Skip to main content
SpringerLink
Log in

Management of type 2 diabetes: finding a sensible pathway through the maze of available agents

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the third national health and nutrition examination survey, 1988–1994. Diabetes Care 1998; 21: 518–24

    Article  PubMed  CAS  Google Scholar 

  2. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000 Jul: 60(1): 95–113

    Article  PubMed  CAS  Google Scholar 

  3. DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 978–86

    Google Scholar 

  4. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study: questions answered and issues remaining. Drugs Aging 2000 Mar: 16(3): 159–64

    Article  PubMed  CAS  Google Scholar 

  5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65

    Article  Google Scholar 

  7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703–13

    Article  Google Scholar 

  8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317: 713–20

    Article  Google Scholar 

  9. Holman RR, Cull CA, Turner RC, et al. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960–4

    Article  PubMed  CAS  Google Scholar 

  10. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928–35

    PubMed  CAS  Google Scholar 

  11. Defronzo RA, Goodman AM, Multicentre Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–92

    Article  PubMed  CAS  Google Scholar 

  12. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737–54

    Article  PubMed  CAS  Google Scholar 

  13. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998; 13: 173–80

    Article  PubMed  CAS  Google Scholar 

  14. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19 Suppl. 2: 747–830

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Management of type 2 diabetes: finding a sensible pathway through the maze of available agents. Drugs Ther. Perspect 17, 4–7 (2001). https://doi.org/10.2165/00042310-200117140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117140-00002

Keywords

Search

Navigation